Topical Carrier Research Articles

Topical calcineurin and mammalian target of rapamycin inhibitors in inflammatory dermatoses: Current challenges and nanotechnology‑based prospects (Review).

Topical therapy remains a critical component in the management of immune‑mediated inflammatory dermatoses such as psoriasis and atopic dermatitis. In this field, macrolactam immunomodulators, including calcineurin and mammalian target of rapamycin inhibitors, can offer steroid‑free therapeutic alternatives. Despite their potential for skin‑selective treatment compared with topical corticosteroids, the physicochemical properties of these compounds, such as high lipophilicity and large molecular size, do not meet the criteria for efficient penetration into the skin, especially with conventional topical vehicles. Thus, more sophisticated approaches are needed to address the pharmacokinetic limitations of traditional formulations. In this regard, interest has increasingly focused on nanoparticulate systems to optimize penetration kinetics and enhance the efficacy and safety of topical calcineurin and mTOR inhibitors in inflamed skin. Several types of nanovectors have been explored as topical carriers to deliver tacrolimus in both psoriatic and atopic skin, while preclinical data on nanocarrier‑based delivery of topical sirolimus in inflamed skin are also emerging. Given the promising preliminary outcomes and the complexities of drug delivery across inflamed skin, further research is required to translate these nanotherapeutics into clinical settings for inflammatory skin diseases. The present review outlined the dermatokinetic profiles of topical calcineurin and mTOR inhibitors, particularly tacrolimus, pimecrolimus and sirolimus, focusing on their penetration kinetics in psoriatic and atopic skin. It also summarizes the potential anti‑inflammatory benefits of topical sirolimus and explores novel preclinical studies investigating dermally applied nanovehicles to evaluate and optimize the skin delivery, efficacy and safety of these 'hard‑to‑formulate' macromolecules in the context of psoriasis and atopic dermatitis.

Overcoming the Challenges in Topical Delivery of Antifungal Agents for Skin Fungal Infections

Fungal infections of the skin are a major global health concern that requires specific and efficient treatment because of their resistant nature. Antifungal drugs used topically present a viable method for targeted therapy with less systemic adverse effects. Nevertheless, a number of challenges impede the effective distribution of these substances, such as restricted skin penetration, inadequate medication retention, and the rise of resistant strains. Overcoming these challenges is very much warranted to minimize the side effects associated with long-term systemic delivery of antifungal agents. This review examines recent developments and approaches to subdue these problems and improve topical antifungal therapy efficacy. The effectiveness of several formulation strategies, including nanotechnology -based treatments, nanostructures, vesicular carriers, Gelling Systems-Polymeric Carriers, and some enhanced targeted therapies in enhancing medication penetration across the epidermal barrier is discussed. Polyenes, azoles, allylamines, echinocandins, hydroxypyridone, and other antifungals are the primary types of antifungal medications. Novel formulation techniques, such as the use of nanostructures, lipid-based carriers, and microneedle technology, show great promise for enhancing medication penetration across the skin barrier and emphasizing the significance of effective topical drug delivery. These tactics not only improve antifungal agent distribution to the intended site but also create opportunities for more focused and effective therapy. This review outlines recent developments in novel strategies used in topical carriers to boost the therapeutic performance of anti-fungal drugs with minimal side effects as compared to systemic therapy.

Topical treatment of tyrosine kinase 2 inhibitor through borneol-embedded hydrogel: Evaluation for preventive, therapeutic, and Recurrent management of psoriasis

Psoriasis, an immune-mediated inflammatory skin disorder characterized by a chronically relapsing-remitting course, continues to be primarily managed through topical therapy. While oral administration of tyrosine kinase 2 inhibitors (TYK2i) stands as an effective approach for psoriasis treatment, the potential efficacy of topical application of TYK2i remains unexplored. Herein, the carbomer/alginic acid hydrogel is embedded with borneol (BO) as a new topical carrier of TYK2i for achieving enhanced transdermal permeation and anti-psoriasis efficacy. The hydrogel system, i.e., TYK2i-BO-gel, exhibits significantly improved preventative and therapeutic effects in mice models of psoriasiform dermatitis, as evidenced by phenotypical images, psoriasis severity score index (PSI), histology, immunohistochemical staining, and PCR analysis. Remarkably, TYK2i-BO-gel outperforms conventional topical corticosteroid therapy by significantly preventing psoriatic lesion recurrence as measured by a nearly 50 % reduction in ear thickness changes (p < 0.0001), PSI (p < 0.0001) and epidermal thickness (p < 0.05). Moreover, a strengthened anti-inflammatory effect caused by TYK2i-BO-gel is seen in a human skin explant model, implying its potential application for human patients. With the addition of BO, the TYK2i-BO-gel not only increases skin permeability but also inhibits the expression of antimicrobial peptides in keratinocytes and facilitates the anti-Th17 response of TYK2i with suppressed activation of STAT3. Therefore, this work represents the accessibility and effectiveness of TYK2i-BO-hydrogel as a new topical formulation for anti-psoriasis management and shows great potential for clinical application.

Recombinant scFv-Fc Anti-kallikrein 7 Antibody-Loaded Thermosensitive Hydrogels Against Skin Desquamation Disorders.

Human tissue kallikrein-related peptidase 7 (KLK7) is a serine protease implicated in the physiology of skin desquamation, and its uncontrolled activity can lead to chronic diseases such as psoriasis, atopic dermatitis, and Netherton syndrome. For this reason, kallikrein 7 has been identified as a potential therapeutic target. This work aimed to evaluate Pluronic (PL) hydrogels as topical carriers of four specific scFv-Fc antibodies to inhibit KLK7. The hydrogels comprised PL F127 (30% w/v) alone and a binary F127/P123 (28-2% w/v) system. Each formulation was loaded with 1 μg/mL of each antibody and characterized by physicochemical and pharmaceutical techniques, considering antibody-micelle interactions and hydrogel behavior as smart delivery systems. Results showed that the antibodies were successfully loaded into the PL-based systems, and the sol-gel transition temperature was shifted to high values after the P123 addition. The antibodies released from the gels preserved their rheological properties (G' > G'', 35- to 41-fold) and inhibitory activity against KLK7, even after 24 h. This work presented potential agents targeting KLK7 that may provide strategies for treating skin abnormalities.

Chitosan/Pomegranate Seed Oil Emulgel Composition as a New Strategy for Dermal Delivery of Hydrocortisone.

Multifunctional delivery systems capable of modulating drug release and exerting adjunctive pharmacological activity have attracted particular attention. Chitosan (CS) and pomegranate seed oil (PO) appear to be attractive bioactive components framing the strategy of complex therapy and multifunctional drug carriers. This research is aimed at evaluating the potential of CS in combination with PO in studies on topical emulgels containing hydrocortisone as a model anti-inflammatory agent. Its particular goal was to distinguish alterations in anti-inflammatory action followed with drug dissolution or penetrative behavior between the designed formulations that differ in CS/PO weight ratio. All formulations favored hydrocortisone release with up to a two-fold increase in the drug dissolution rate within first 5 h as compared to conventional topical preparations. The clear effect of CS/PO on the emulgel biological performance was observed, and CS was found to be prerequisite for the modulation of hydrocortisone absorption and accumulation. In turn, a greater amount of PO played the predominant role in the inhibition of hyaluronidase activity and enhanced the anti-inflammatory effect of preparation E-3. Emulgels showed a negligible reduction in mouse fibroblasts' L929 cell viability, confirming their non-irritancy with skin cells. Overall, the designed formulation with a CS/PO ratio of 6:4 appeared to be the most promising topical carrier for the effective treatment of inflammatory skin diseases among the tested subjects.

Formulation Development and Evaluation of Microemulsion Loaded Hydrogel Systems with Plant Bioactives in Combination for Treatment of Psoriasis

Psoriasis is an autoimmune, long-lasting skin disorder affecting about 1 to 3% of the world’s population. Plant bio-actives like flavonoids, alkaloids, glycosides, terpenoids, phenolic acids, peptides, tannins, etc., are considered as the best alternative over synthetic drugs, especially for the topical treatment of such chronic skin ailments to avoid side effects of such synthetic agents. The present study aims at the formulation and characterization of novel topical carrier systems for the incorporation of plant bioactive molecules from the class of alkaloids and flavonoids so as to enhance the therapeutic efficacy, bypass the side effects of synthetic drugs, and improve drug localization in the diseased skin to achieve site-specific action. This work created oil, surfactant, and co-surfactant formulations of plant bio-actives using oleic acid, polysorbate 80, and propylene glycol. Different batches of microemulsions with surfactant: Cosurfactant composition ranging from 25 to 34.8% were prepared and were embedded in a hydrogel system containing gelling agents like sodium alginate and carbapol 940 to get ease of topical application in the treatment of psoriasis. These developed micro-emulates (microemulsion loaded hydrogels) were evaluated for various parameters like viscosity, spreadability, content uniformity, microscopic examination, globule size, zeta potential, polydispersibility index, centrifugation test, dilution test, dye test, percent transmittance, conductivity test, etc. The developed formulations were pharmaceutically stable and efficient.

Targeting Potential of Zinc Oxide Nanoparticles and Finasteride-loaded Nano Lipidic Carriers-infused Topical Gel - In vitro and In vivo Skin Permeation Studies

Background: There is an unmet clinical need to develop topical carriers for finasteride to reduce its systemic side effects in the treatment of androgenic alopecia (AGA). Zinc oxide (ZnO) nanoparticles have also emerged as an influential agent in hair biology. Aim: The main focus of the work was to develop a novel formulation to explore the potential of ZnO nanoparticles in combination with NLCs of finasteride (FIN) for topical delivery. Method: ZnO nanoparticles were synthesized by precipitation method and were subsequently incorporated within the Carbopol gel. The ZnO nanoparticles and the gel were evaluated for their physicochemical characteristics. In vitro release study was performed for the determination of release of the drugs from the gel and ex vivo study was conducted for the determination of penetration of the NLCs and ZnO nanoparticles into the skin. Result: The particle size of the nanoparticles was found to be 200 nm. The pH, viscosity and spreadability of the gel was observed to be 6.13±2.11, 35,845.3±6.97 cps at 5 rpm and 17.14±2.32 respectively. Ex vivo drug permeation and skin distribution studies of the NLC gel formulations carried on rat dorsal skin indicated 25.763±0.2 μg/cm² and 19.375±1.2 μg/cm² of FIN and ZnO in 12 hr respectively. Conclusion: The results indicated the potential of developed systems for topical drug delivery for treatment of androgenic alopecia.

Spanethosomes as a novel topical carrier for silymarin in contrast to conventional spanlastics: Formulation development, in vitro and ex vivo evaluation for potential treatment of leishmaniasis

Spanethosomes as a novel topical carrier for silymarin in contrast to conventional spanlastics: Formulation development, in vitro and ex vivo evaluation for potential treatment of leishmaniasis

Formulation and evaluation of a novel controlled release mefenamic acid pluronic lecithin organogel

Based on pluronic lecithin, PLO gels were established in the present research as a topical carrier for the regulated delivery of mefenamic acid. To explore various factors utilizing In vitro diffusion experiments and in vivo study, ten organized formulations have been created using such methods that used lecithin as a lipophilic phase as well as pluronic F-127 as a hydrophilic phase in variable proportions. The pH values of all formulations were found to be between 5.60 and 5.75, which is nonirritating, and to be off-white, homogeneous, and unwilling to wash off easily. In formulations F1 to F5 (lecithin) but also F6 to F10 (pluronic), an increase in polymer concentration led to a drop in gelation temperature, an increase in viscosity, as well as a reduction within the spreadability of gels with a tendency for polymers to form rigid 3D networks. Higher viscosity organogels have been proven to be more stable and delay drug release from the gel. The formulations of F2 and F3 have been chosen for kinetic tests and stability studies because they had the most significant percentage of drug content and the highest drug release during eight hours, and all physical parameters were found to be within acceptable limits. It was discovered that the order of drug release through different formulations was F1to F10. A drug is removed from the improved formulation F2 in a regulated manner according to zero-order rate kinetics. The optimized mefenamic acid organogel (F2) in vivo anti-inflammatory effectiveness against a commonly used commercial product (Volini gel) was determined to be satisfactory but also significant.

L-Cysteine-Modified Transfersomes for Enhanced Epidermal Delivery of Podophyllotoxin.

The purpose of this study was to evaluate L-cysteine-modified transfersomes as the topical carrier for enhanced epidermal delivery of podophyllotoxin (POD). L-cysteine-deoxycholic acid (LC-DCA) conjugate was synthesized via an amidation reaction. POD-loaded L-cysteine-modified transfersomes (POD-LCTs) were prepared via a thin membrane dispersion method and characterized for their particle size, zeta potential, morphology, X-ray diffraction (XRD), Fourier transform infrared spectroscopy (FTIR) and in vitro release. Subsequently, in vitro skin permeation and retention, fluorescence distribution in the skin, hematoxylin-eosin staining and in vivo skin irritation were studied. The POD-LCTs formed spherical shapes with a particle size of 172.5 ± 67.2 nm and a zeta potential of -31.3 ± 6.7 mV. Compared with the POD-Ts, the POD-LCTs provided significantly lower drug penetration through the porcine ear skin and significantly increased the skin retention (p < 0.05). Meaningfully, unlike the extensive distribution of the POD-loaded transfersomes (POD-Ts) throughout the skin tissue, the POD-LCTs were mainly located in the epidermis. Moreover, the POD-LCTs did not induce skin irritation. Therefore, the POD-LCTs provided an enhanced epidermal delivery and might be a promising carrier for the topical delivery of POD.

A biocompatible lipid-based bigel for topical applications

The development of biocompatible delivery systems is a necessity for medical and topical applications. Herein, the development of a new bigel for topical application is described. It is composed of 40% colloidal lipid hydrogel and 60% olive oil and beeswax oleogel. Its characterization and the potential of the bigel as a drug carrier through the skin was evaluated in vitro using fluorescence microscopy and two phases of the bigel were labeled with two fluorescent probes: sodium fluorescein (hydrophilic phase) and Nile red (lipophilic phase). The structure of the bigel showed two phases with fluorescence microscopy in which the hydrogel phase was incorporated into a continuous oleogel matrix. Attenuated Total Reflectance Fourier Transform Infrared Spectroscopy (ATR-FTIR) presented a combination of vibrations characteristic of the different molecules forming the bigel, and Differential Scanning Calorimetry (DSC) showed different transitions attributed to beeswax lipids. Small-angle and wide-angle X-ray scattering (SAXS and WAXS) indicated a predominant lamellar structure with orthorhombic lateral packing that could be related to the arrangement of beeswax crystals. Bigel enables deeper penetration of hydrophilic and lipophilic probes into deeper layers, making it a promising candidate for effective topical carriers in medical and dermatological applications.

Anti-Inflammatory Salidroside Delivery from Chitin Hydrogels for NIR-II Image-Guided Therapy of Atopic Dermatitis.

Atopic dermatitis (AD) is the most common heterogeneous skin disease. Currently, effective primary prevention approaches that hamper the occurrence of mild to moderate AD have not been reported. In this work, the quaternized β-chitin dextran (QCOD) hydrogel was adopted as a topical carrier system for topical and transdermal delivery of salidroside for the first time. The cumulative release value of salidroside reached ~82% after 72 h at pH 7.4, while in vitro drug release experiments proved that QCOD@Sal (QCOD@Salidroside) has a good, sustained release effect, and the effect of QCOD@Sal on atopic dermatitis mice was further investigated. QCOD@Sal could promote skin repair or AD by modulating inflammatory factors TNF-α and IL-6 without skin irritation. The present study also evaluated NIR-II image-guided therapy (NIR-II, 1000-1700 nm) of AD using QCOD@Sal. The treatment process of AD was monitored in real-time, and the extent of skin lesions and immune factors were correlated with the NIR-II fluorescence signals. These attractive results provide a new perspective for designing NIR-II probes for NIR-II imaging and image-guided therapy with QCOD@Sal.

Formulation and Characterization of Oleogel as a Topical Carrier of Azithromycin

This study aims to formulate azithromycin oleogel to locally treat skin infections such as acne vulgaris and skin wound infection. Providing a form of azithromycin that can be administered topically is highly desired to prevent unwanted systemic complications including diarrhea, nausea, and abdominal pain. Additionally, it will avoid first pass metabolism, improves patient acceptance, provides an alternative in nauseated patients, decreases the dose by direct contact with the pathological site, and provides a noninvasive and convenient mode of administration. Furthermore, for treating wound infections, the gel will act as a scaffold biomaterial for wound closure besides its antibacterial effect. Herein, we propose the use of grapeseed oil-based oleogel with glycerol monostearate (GMS) as an organogelator as a promising strategy for the effective topical delivery of azithromycin. A series of oleogels were prepared by varying concentrations of organogelators namely GMS, palmitic acid, Compritol 888, and stearic acid, while maintaining the weight ratio of grapeseed oil and clove oil constant. Initial evaluation showed azithromycin oleogel with 15% GMS to be the optimum formulation and it was selected for further evaluation. In vivo testing of the formulated gel showed significant effectiveness in promoting faster clinical healing of Staphylococcus aureus infected wounds. The findings of the present study suggest that azithromycin oleogel is stable, safe, cost-effective, and it provides significant antibacterial activity.

Nanostructured-lipid carriers-Chitosan hydrogel beads carrier system for loading of resveratrol: A new method of topical application.

The aim of this study was to develop nanostructured-lipid carriers (NLC) encapsulated by Chitosan hydrogel beads for the efficient topical carrier. Dynamic light scattering (DLS), X-ray diffraction (XRD), Differential scanning calorimetry (DSC), and attenuated total reflectance-Fourier transform infrared spectroscopy (ATR-FTIR) were conducted to study the influence of the encapsulation on the characteristic of resveratrol-loaded NLC, and the results showed that there was no impact on resveratrol-loaded NLC. Chitosan hydrogel beads could significantly improve the physical stability of resveratrol-loaded NLC. In vitro release study revealed that resveratrol-loaded NLC-Chitosan hydrogel beads had a more significant sustained-release effect on resveratrol. In vitro transdermal studies suggested that the skin permeation of resveratrol was promoted by the effect of Chitosan hydrogel beads and increased resveratrol distribution in the skin. In vitro cytotoxicity showed that resveratrol-loaded NLC-Chitosan hydrogel beads did not exert a hazardous effect on L929 cells. Hence, NLC-Chitosan hydrogel beads might be a promising method for topical applications of resveratrol.

EtoGel for Intra-Articular Drug Delivery: A New Challenge for Joint Diseases Treatment.

Ethosomes® have been proposed as potential intra-articular drug delivery devices, in order to obtain a longer residence time of the delivered drug in the knee joint. To this aim, the conventional composition and preparation method were modified. Ethosomes® were prepared by using a low ethanol concentration and carrying out a vesicle extrusion during the preparation. The modified composition did not affect the deformability of ethosomes®, a typical feature of this colloidal vesicular topical carrier. The maintenance of sufficient deformability bodes well for an effective ethosome® application in the treatment of joint pathologies because they should be able to go beyond the pores of the dense collagen II network. The investigated ethosomes® were inserted in a three-dimensional network of thermo-sensitive poloxamer gel (EtoGel) to improve the residence time in the joint. Rheological experiments evidenced that EtoGel could allow an easy intra-articular injection at room temperature and hence transform itself in gel form at body temperature into the joint. Furthermore, EtoGel seemed to be able to support the knee joint during walking and running. In vitro studies demonstrated that the amount of used ethanol did not affect the viability of human chondrocytes and nanocarriers were also able to suitably interact with cells.

Hyaluronic acid incorporation into nanoemulsions containing Pterodon pubescens Benth. Fruit oil for topical drug delivery

Abstract There is growing interest in the use of topical delivery systems that can modify the permeation of drugs through the skin. Transdermal carriers containing hyaluronic acid have been investigated, and results indicate that nanoemulsions containing hyaluronic acid can be used successfully in delivery systems of lipophilic drugs. Pterodon pubescens oil be widely used due to its anti-inflammatory, antirheumatic, leishmanicidal, and antiproliferative activities. In this study, the effect of the incorporation of hyaluronic acid on the physicochemical properties and physical stability of topical nanostructured systems containing P.pubescens fruit oil was investigated. Nanoemulsions were prepared using an Ultra-Turrax homogenizer. The droplet diameter varied from 16.33 ± 0.30 to 26.63 ± 0.21 nm. The zeta potential for nanoemulsions with hyaluronic acid indicated good physical stability. The thermogravimetric and differential scanning calorimetry analyses showed that the nanoemulsions were able to protect the vegetable oil from thermal degradation. The nanoemulsions containing hyaluronic acid presented a pseudoplastic flow behavior, and a lower instability index than the formulations without hyaluronic acid in accelerated physical stability study. In conclusion, the incorporation of hyaluronic acid altered the physical characteristics of the evaluated systems, providing favorable properties for the use of these nanoemulsions as topical carriers.

Non-ionic surfactant vesicles as a carrier system for dermal delivery of (+)-Catechin and their antioxidant effects

Numerous skin disorders and diseases are related to oxidative stress. The application of an antioxidant, serving as a strong defense agent against oxidation, is of great interest in dermatology yet remains challenging for delivery. This paper aimed to develop a niosome carrier system to deliver the antioxidant (+) Catechin into the skin. (+) Catechin-loaded niosomes were prepared using film hydration technique and the physicochemical properties of drug-loaded niosomes were characterised and investigated by a series of in vitro and ex vivo studies. The optimised formulation displayed an acceptable size in nanoscale (204 nm), high drug entrapment efficiency (49%) and amorphous state of drug in niosomes. It was found that (+) Catechin-loaded niosomes could effectively prolong the drug release. Drug deposition in the viable layers of human skin was significantly enhanced when niosomal carriers were applied (p < 0.05). Compared to the pure drug, the niosomal formulation had a greater protective effect on the human skin fibroblasts (Fbs). This is consistent with the observation of internalisation of niosomes by Fbs which was concentration-, time- and temperature-dependent, via an energy-dependent process of endocytosis. The research highlighted that niosomes are potential topical carriers for dermal delivery of antioxidants in skin-care and pharmaceutical products.

In Vitro Skin Permeation and Antifungal Activity of Naftifine Microemulsions.

Microemulsions are fluid, isotropic, colloidal systems that have been widely studied as drug delivery systems. The percutaneous transport of active agents can be enhanced by their microemulsion formulation when compared to conventional formulations. The purpose of this study was to evaluate naftifine-loaded microemulsions with the objective of improving the skin permeation of the drug. Microemulsions comprising oleic acid (oil phase), Kolliphor EL or Kolliphor RH40 (surfactant), Transcutol (co-surfactant), and water were prepared and physicochemical characterization was performed. In vitro skin permeation of naftifine from microemulsions was investigated and compared with that of its conventional commercial formulation. Attenuated total reflectance-Fourier transform infrared (ATR-FTIR) spectroscopy was used to evaluate the interaction between the microemulsions and the stratum corneum lipids. Candida albicans American Type Culture Collection (ATCC) 10231 and Candida parapsilosis were used to evaluate the antifungal susceptibility of the naftifine-loaded microemulsions. The microemulsion formulation containing Kolliphor RH40 as co-surfactant increased naftifine permeation through pig skin significantly when compared with the commercial topical formulation (p<0.05). ATR-FTIR spectroscopy showed that microemulsions increased the fluidity of the stratum corneum lipid bilayers. Drug-loaded microemulsions possessed superior antifungal activity against Candida albicans ATCC 10231 and Candida parapsilosis. This study demonstrated that microemulsions could be suggested as an alternative topical carrier with potential for enhanced skin delivery of naftifine.

Sulforaphane-Loaded Ultradeformable Vesicles as A Potential Natural Nanomedicine for the Treatment of Skin Cancer Diseases.

Sulforaphane is a multi-action drug and its anticancer activity is the reason for the continuous growth of attention being paid to this drug. Sulforaphane shows an in vitro antiproliferative activity against melanoma and other skin cancer diseases. Unfortunately, this natural compound cannot be applied in free form on the skin due to its poor percutaneous permeation determined by its physico-chemical characteristics. The aim of this investigation was to evaluate ethosomes® and transfersomes® as ultradeformable vesicular carriers for the percutaneous delivery of sulforaphane to be used for the treatment of skin cancer diseases. The physico-chemical features of the ultradeformable vesicles were evaluated. Namely, ethosomes® and transfersomes® had mean sizes <400 nm and a polydispersity index close to 0. The stability studies demonstrated that the most suitable ultradeformable vesicles to be used as topical carriers of sulforaphane were ethosomes® made up of ethanol 40% (w/v) and phospholipon 90G 2% (w/v). In particular, in vitro studies of percutaneous permeation through human stratum corneum and epidermis membranes showed an increase of the percutaneous permeation of sulforaphane. The antiproliferative activity of sulforaphane-loaded ethosomes® was tested on SK-MEL 28 and improved anticancer activity was observed in comparison with the free drug.

Evaluation of chamomile oil and nanoemulgels as a promising treatment option for atopic dermatitis induced in rats

ABSTRACTBackground: Atopic dermatitis is a chronic inflammatory skin disease that remarkably affects the quality-of-life of patients. Chamomile oil is used to treat skin inflammations. We evaluated the efficacy of chamomile oil and nanoemulgel formulations as a natural alternative therapeutic option for atopic dermatitis.Research design and methods: Formulations were developed comprising chamomile oil: olive oil (1:1), Tween 20/80 or Gelucire 44/14 as surfactant-cosurfactant mixtures, propylene glycol (10%w/w), water and hydroxypropyl methylcellulose (3%w/w). In-vitro physicochemical characterization, stability testing and in-vivo assessment of inflammatory biomarkers and histopathological examination of skin lesions were conducted in rats induced with atopic dermatitis.Results: Nanoemulgels G1 and X1 which displayed the smallest particle size of 137.5 ± 2.04 and 207.1 ± 5.44 nm, good homogeneity and high zeta-potential values of –26.4 and –32.7 mV were selected as the optimized emulgel. Nanoemulgels were nonirritating of pH value 5.56, readily spreadable, and were physically stable following 10 heating-cooling cycles. Treatment with nanoemulgels showed a two-fold decrease in duration of skin healing and no spongiosis compared to chamomile oil. Levels of biomarkers were reduced after topical application of both nanoemulgels and chamomile oil.Conclusion: Nanoemulgels are a potential cost effective, safe topical carrier system for chamomile in treating atopic dermatitis.